These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27941286)

  • 41. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
    Magee MS; Snook AE
    Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
    Stauss HJ; Morris EC
    Gene Ther; 2013 Nov; 20(11):1029-32. PubMed ID: 23804078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
    Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
    Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical development of T cell receptor gene therapy.
    Bendle GM; Haanen JB; Schumacher TN
    Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Basics of cancer immunotherapy].
    Fujioka Y; Nishikawa H
    Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.
    Fujiwara H
    Pharmaceuticals (Basel); 2014 Dec; 7(12):1049-68. PubMed ID: 25517545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Recent advances and future challenges in cancer immunotherapy].
    Okuyama N; Tamada K; Tamura H
    Rinsho Ketsueki; 2016; 57(11):2388-2395. PubMed ID: 27941290
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines.
    Solomon BJ; Beavis PA; Darcy PK
    Am Soc Clin Oncol Educ Book; 2020 May; 40():1-6. PubMed ID: 32412805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. International Regensburg Center for Interventional Immunology (RCI) symposium on "Synthetic immunology and environment-adapted redirection of T cells", 17-18 July, 2019, Regensburg, Germany.
    Beckhove P; Edinger M; Feuerer M; Gattinoni L; Abken H
    Cancer Immunol Immunother; 2020 Apr; 69(4):677-682. PubMed ID: 32123937
    [No Abstract]   [Full Text] [Related]  

  • 51. Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia.
    Campillo-Davo D; Anguille S; Lion E
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The nephrotoxicity of new immunotherapies.
    Sury K; Perazella MA
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):513-521. PubMed ID: 31035801
    [No Abstract]   [Full Text] [Related]  

  • 53. Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors.
    Brocker T; Karjalainen K
    Adv Immunol; 1998; 68():257-69. PubMed ID: 9505091
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunology and Immunotherapy in Critical Care: An Overview.
    Munro N
    AACN Adv Crit Care; 2019; 30(2):113-125. PubMed ID: 31151943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Driving T-cell immunotherapy to solid tumors.
    Garber K
    Nat Biotechnol; 2018 Mar; 36(3):215-219. PubMed ID: 29509745
    [No Abstract]   [Full Text] [Related]  

  • 56. [Recent progress of cancer immunology and immunotherapy].
    Kawakami Y
    Nihon Rinsho; 2017 Feb; 75(2):175-180. PubMed ID: 30562849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antigen-specific immunotherapy for autoimmune diseases.
    Yamamoto K; Okamoto A; Fujio K
    Expert Opin Biol Ther; 2007 Mar; 7(3):359-67. PubMed ID: 17309327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
    Muranski P; Boni A; Wrzesinski C; Citrin DE; Rosenberg SA; Childs R; Restifo NP
    Nat Clin Pract Oncol; 2006 Dec; 3(12):668-81. PubMed ID: 17139318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytotoxic CD8
    Raskov H; Orhan A; Christensen JP; Gögenur I
    Br J Cancer; 2021 Jan; 124(2):359-367. PubMed ID: 32929195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome.
    Tanaka TN; Ferrari V; Tarke A; Fields H; Ferrari L; Ferrari F; McCarthy CL; Sanchez AP; Vitiello A; Lane TA; Bejar R
    Cytotherapy; 2021 Mar; 23(3):236-241. PubMed ID: 33279399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.